Synonym
tCUPM; t CUPM; t-CUPM
IUPAC/Chemical Name
trans-4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-cyclohexyloxy}-pyridine-2-carboxylic acid methylamide
InChi Key
VZOUKWZMPPMODY-MQMHXKEQSA-N
InChi Code
InChI=1S/C21H22ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h4,7-12,14H,2-3,5-6H2,1H3,(H,26,30)(H2,28,29,31)/t12-,14-
SMILES Code
O=C(C1=NC=CC(O[C@H]2CC[C@H](NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)CC2)=C1)NC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
470.88
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Liao J, Hwang SH, Li H, Liu JY, Hammock BD, Yang GY. Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice. Anticancer Res. 2016 Jan;36(1):27-37. PubMed PMID: 26722025; PubMed Central PMCID: PMC4793710.
2: Liao J, Hwang SH, Li H, Yang Y, Yang J, Wecksler AT, Liu JY, Hammock BD, Yang GY. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM. Cancer Lett. 2016 Feb 28;371(2):187-93. doi: 10.1016/j.canlet.2015.11.042. Epub 2015 Dec 9. PubMed PMID: 26683769; PubMed Central PMCID: PMC4738175.
3: Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD. Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol. 2015 Jan;75(1):161-71. doi: 10.1007/s00280-014-2626-2. Epub 2014 Nov 21. PubMed PMID: 25413440; PubMed Central PMCID: PMC4400119.
4: Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3732-7. doi: 10.1016/j.bmcl.2013.05.011. Epub 2013 May 15. PubMed PMID: 23726028; PubMed Central PMCID: PMC3744640.
